Cellid Co.,Ltd. leads development of anti-cancer immunotherapy.
Original CeliVax Technology
The immunological adjuvant, α-galactosyl ceramide, binds to CD1d molecule of B cells and monocytes and induces the activation of Natural Killer T (NKT) cells.
- α-galactosyl ceramide mediates the interaction between the B cells/monocytes and Natural Killer T cells. NKT cells activated by the interaction release various kinds of immune boosting cytokines to activate a broad spectrum of immune responses.